Efetividade e segurança do ácido zoledrônico intravenoso no tratamento da osteoporose pós-menopausal: revisão sistemática

• Ano de defesa: 2009
• Autor(a) principal: Albergaria, Ben-Hur [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Ensaios clínicos controlados randomizados; Revisão sistemática; Ácido zoledrônico; Osteoporose pós- menopausal; Metanálise
• Link de acesso: http://repositorio.unifesp.br/handle/11600/9440

Introduction: The osteoporosis is a skeletal disorder characterized by the compromising of the bone strength, that predisposes to an increase in the risk of fractures; it is, therefore, an important cause of morbidity, mortality and loss of the life quality among postmenopausal. The bisphosphonates, agents that inhibit the bone reabsorption mediated by the osteoclasts, constitute, at the present time, the first-line treatment for the postmenopausal osteoporosis. They have been demonstrating reduction in the risk of vertebral and non vertebral fractures in postmenopausal women , but the low adhesion to the treatment is still a challenge that commits the effectiveness of this intervention. The use of an intermittent regimen of the zoledronic acid, a new and potent bisphosphonate , administered intravenously in an annual infusion, seems to constitute a promising alternative to the daily or weekly oral administration of the others bisphosphonates. However, a systematic revision of the literature is obligatory to define how effective and safe is the zoledronic acid for the treatment of the osteoporosis in postmenopausal women. Objective: to determine the effectiveness and safety of the zoledronic acid in the treatment of the postmenopausal osteoporosis. Methods: search strategy - a) online: PUBMED, BASE, LILACS, CENTRAL (COCHRANE LIBRARY); b) hand search :list of references. Selection criteria - a)types of studies: all of the controlled and randomized studies eligible; b): types of participants: only trials with postmenopausal women will be include; d)types of interventions: trials with zoledronic acid versus placebo or active comparator; d) types of outcome measures: percent changes in bone mineral density and biochemical bone markers; number of fractures, including vertebral and non vertebral fractures; toxicity; e) data collection and analyses: three reviewers will inspect, in an independent way, the references found by the search strategy and they will apply the inclusion criteria in the selected studies, using the criteria of methodological quality described in Cochrane Handbook.